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A prospective randomized trial comparing the clinical effectiveness and 
biocompatibility of heparin coated circuits and PMEA-coated circuits in pediatric 
cardiopulmonary bypass 
 
ABSTRACT 
We compared the clinical effectiveness and biocompatibility of poly-2-methoxyethyl 
acrylate (PMEA)-coated and heparin-coated cardiopulmonary bypass (CPB) circuits in 
a prospective pediatric trial.     
Infants randomly received heparin-coated (n=7) or PMEA-coated (n=7) circuits 
in elective pediatric cardiac surgery with CPB for ventricular septum defects. Clinical 
and hematologic variables, respiratory indices, and hemodynamic changes were 
analyzed perioperatively. Demographic and clinical variables were similar in both 
groups. Leukocyte counts were significantly lower 5 minutes after CPB in the PMEA 
group than the heparine group. Hemodynamic data showed that PMEA caused 
hypotension within 5 minutes of CPB. The respiratory index was significantly higher 
immediately after CPB and 1 hour after transfer to the intensive care unit (ICU) in the 
PMEA group, as were levels of C-reactive protein 24 hours after transfer to the ICU.  
Our study shows that PMEA-coated circuits, unlike heparin-coated circuits, 
cause transient leukopenia during pediatric CPB and perhaps systemic inflammatory 
respiratory syndrome after pediatric CPB.  (153 words) 
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Introduction 
Cardiopulmonary bypass (CPB) induces inflammatory responses and increases 
postoperative morbidity. Contact between the blood and the artificial surface of the CPB 
circuit produces post-perfusion syndrome, which in severe cases causes systemic 
inflammatory response syndrome (SIRS), acute respiratory district syndrome and other 
acute lung injuries, sepsis, and even multiple organ failure.1-5 To improve the 
biocompatibility of non-physiological surfaces and thus reduce the incidence of 
systemic inflammatory responses, the medical device industry has developed different 
coating materials for CPB circuits.2, 6 -10 
Since the first description of heparin bonding on colloidal graphite surfaces in 
1963,11 preparing CPB circuits with biocompatible materials has increased in 
importance. Heparin-coated CPB circuits can potentially decrease postoperative blood 
loss as well as the need to transfuse blood and blood products.6 They can also reduce 
complement activation and subsequent cytokine release.12, 13 
   It has been reported that heparin-coated circuits reduce CPB-induced 
inflammation.7 Poly-2-methoxyethyl acrylate (PMEA)-coated circuits have good 
biocompatibility, 8 and PMEA is one of the best blood-compatible polymers, as 
determined via various approaches.8, 12 Although it is currently being used for practical 
applications such as oxygenators and the tubes in CPB circuits, how it produces blood 
compatibility is still not fully understood.14 
   Modification of the blood-contacting surfaces in CPB circuits has been shown 
to increase platelet number, improve platelet function, and decrease fibrinolysis, and 
inflammation after cardiac surgery in adults.15 However, there have been only a few 
studies of the influence of hematologic changes on clinical results in pediatric patients. 
When larger CPB circuits and higher flow rates are used, better outcomes in congenital 
heart surgery might be expected.3, 15-17 
   We compared the biological effectiveness and biocompatibility of PMEA-
coated and heparine-coated circuits in pediatric cardiac surgery with CPB. 
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Material and Methods 
Studies on human subjects were performed according to the principles of the 
Declaration of Helsinki. The patients’ parents received a detailed description of the 
operative procedures and provided informed consent. The Okayama University 
Institutional Investigational Review Board approved the project.  
Fourteen infants aged 3 to 5 months who required elective pediatric cardiac 
surgery with CPB for ventricular septal defects were enrolled in this study. The patients 
were randomly divided into two groups by drawing cards from sealed envelopes ; the 
heparin group received heparin-coated circuits (n=7), and PMEA group received 
PMEA-coated circuits (n=7).  
  
Surgical procedure 
For CPB, we used a hollow-fiber membrane oxygenator (RX-05; Terumo, Tokyo), an 
open hard-shell reservoir (Baby-RX; Terumo), an arterial filter (CX-AF02; Terumo), 
and a roller pump for perfusion (HAS; MERA, Tokyo). All blood-containing surfaces 
except the cannulae in the CPB circuit were heparin-coated or PMEA-coated; both 
types of circuits were obtained from TERUMO. The bypass tubing set consisted of a 
3/16 inch × 1/4 inch A-V loop coated with heparin or PMEA and a 1/4 inch pump boot. 
The only difference between the CPB circuits was the coating material of the tubing; 
i.e., either heparin or PMEA. 
The extracorporeal circuit and the oxygenator were primed with acetate 
Ringer’s solution, mannitol, riboflavin sodium phosphate, and sodium bicarbonate. We 
used a CDI 500 arterial gas and venous saturation hematocrit monitor (Terumo) and 
maintained the hematocrit level at more than 25% during CPB by adding packed red 
blood cells. Systemic anticoagulation was achieved via intravenous heparin (4 mg/kg) 
administration. After administration of an initial pre-CPB dose of heparin (300 IU/kg), 
activated clotting time (ACT) was maintained at more than 400 seconds during CPB. 
Intra-operative management was the same in both groups. The initial 
cardiopulmonary perfusion flow rate was 150−180 mL/min per kg to maintain venous 
saturation above 80%. Perfusion pressures were maintained at 40−60 mmHg. Moderate 
hypothermia (30−32℃) was applied to all patients. Normal systemic vascular resistance 
was maintained via administration of methoxiamine hydrochloride (1 mg/kg) and 
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chlorpromazine hydrochloride (0.5−1.0 mg/kg). Blood gasses were regulated according 
to the alpha-stat regimen, and sodium bicarbonate was administered when the base 
excess dropped below -3.0 mmol/L. We used dilutional ultrafiltration with a 
polyethersulfone membrane (Aquastream AS-04; JMS, Tokyo) and bispectral index 
monitoring (40−70; ASPECT; Aspect Medical Systems, Boston, MA) during CPB. 
Modified ultra filtration (MUF) was performed in all cases. 
 
Anesthesia 
Anesthesia was induced via intravenous injection of high-dose fentanyl (total, 50−150 
µg/kg), midazolam (0.2-0.4 mg/kg), and pancuronium (0.1 mg/kg). All patients were 
weaned from CPB via intravenous infusion of dopamine (5 µg/kg per min), dobutamine 
(5 µg/kg per min), and/or nitroglycerine (1 µg/kg per min). Some patients required 
intravenous infusion of these inotropes and vasodilators at higher doses for successful 
weaning from CPB. When necessary, chlorpromazine hydrochloride (1.0 mg/kg) was 
used during the rewarming phase. Anticoagulation was reversed using intravenous 
protamine sulfate (3 mg/kg).  
 
Blood sampling and biochemical analysis 
Blood was drawn through a syringe into a cuvette within an ABL800 FLEX 
(Radiometer Medical, Copenhagen, Denmark) gas analyzer set at 37℃. One microliter 
of the specimen was hemolyzed via ultrasound (30kHz), and hemoglobin content was 
assessed spectrophotometrically at 128 different wave lengths (478− 672 nm). The 
hemoglobin content of the blood sample was determined using the Lambert-Beer 
hemoglobin equation; hematocrit content was based on hemoglobin content and 
determined using an internal algorithm. Serum hemoglobin, erythrocyte, thrombocyte 
and leukocyte levels were measured using an ADVIA 2120 hematology system 
(Siemens AG, Eschborn, Germany) and the following methods: a novel cyanide-free 
colorimetric method (serum hemoglobin), cytograms (erythrocytes and thrombocytes) 
and flow cytometry and cytochemical peroxidase staining (leukocyte). Amount of total 
protein, C-reactive protein (CRP), and albumin in serum, were measured using a JCA-
BM 8040 automated analyzer (JEOL, Tokyo, Japan) and the CRP-Latex (Ii) X2 assay 
(CRP) and the 2-reagent biuret method, modified bromocresol purple method 
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(albumin).  
Arterial blood (for measurement of hemoglobin, erythrocyte, leukocyte, 
thrombocytes, D-dimer fibrin, and total protein levels) was sampled at 7 time points: (1) 
after induction of anesthesia, (2) just before CPB (5 minutes after heparin 
administration), (3) 5 minutes after CPB, (4) 30 minutes after CPB, (5) after CPB (5 
minutes after protamine sulfate administration), (6) 24 hours after admittance to the 
intensive care unit (ICU), and (7) just before discharge from the ICU. Albumin and 
serum globulin were sampled at 3 time points: (1) after induction of anesthesia, (2) 24-
hours after admittance to the ICU, and (3) just before discharge from the ICU. C-
reactive protein (CRP) was sampled at 4 time points: (1) just before CPB, (2) after 1 
hour after admittance to the ICU, (3) 24 hours after admittance to the ICU, (4) just 
before discharge from the ICU. At each time point, 5 mL of blood were withdrawn. Two 
milliliters of the blood sample were used for ACT measurement, 2 mL for biochemical 
examination of the blood, including CRP and D-dimer levels, and 0.5 mL for blood gas 
analysis and electrolyte measurement. The medical laboratory at the Okayama 
University Hospital performed all assays.  
 
Respiratory index (RI) 
The RI is an indicator of oxygenation due to various pulmonary complications. To 
standardize alveolar-arterial oxygen gradients to the inspired fraction of oxygen during 
ventilation, the RI was calculated as follows: alveolar-arterial oxygen tension 
gradient/arterial oxygen tension. Calculations were made immediately before and after 
CPB, 1 hour after admittance to the ICU, and immediately before extibation. 
 
Hemodynamic monitoring 
Hemodynamic data were compared between the two groups intra-operatively and post-
operatively. The data included systolic arterial pressure (SAP), mean arterial pressure 
(MAP), and diastolic arterial pressure (DAP). Hemodynamic monitoring data were 
recorded at 5 time points: (1) just before CPB (5 minutes after heparin administration), 
(2) 5 minutes after CPB, (3) just after aortic clamp-off, (4) just after CPB, and (5) 1 
hour after admittance to the ICU. 
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Clinical outcome 
The following items were recorded:the time of mechanical ventilator support; 
postoperative blood loss; amounts of transfused packed red blood cells, fresh frozen 
plasma (FFP), and platelets; the length of hospitalization, and morbidity and mortality 
rates. Ventilation was measured from the end of surgery to the time of tracheal 
extubation. Patients were discharged from hospital when they were apyrexial, in an 
overall satisfactory stable condition, and able to perform basic routine tasks. Mortality 
was defined as all-cause, 30-day.  
 
 
Statistical analysis 
Data were analyzed using SPSS software for windows version 20 (SPSS Inc, Chicago, 
IL). All data were expressed as median and range. The χ2 and Kruskal-Wallis tests were 
used to evaluate differences between groups for statistical significance. A p-value of 
<0.05 was considered to have statistical significance. A sample power of 3.0 was used 
for all data to determine the number of samples necessary for detecting statistically 
significant differences between the two groups.18, 19 Power analyses were conducted 
using MANOVA comparisons, a significance level of 0.05, and a power of 0.6. 
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Results 
There were no complications or mortalities. Patient demographic data and clinical 
variables are summarized in Table 1. There were no differences between the heparin and 
PMEA groups in sex, age, weight, or body surface area. Operative and CPB parameters 
(CPB time, aortic cross-clamp time, minimum temperature during CPB, filtration 
volume during CPB and MUF, and urine output and bleeding during surgery were also 
similar as were postoperative parameters (urine, and chest tube output in the first 24 
hours after surgery; amounts of packed red blood cells, FFP, and platelets transfused in 
the first 24 hours after surgery; time to extubation; and hospital stay). In contrast, the 
amount of packed red blood cells transfused during surgery was significantly higher in 
the PMEA group than the heparin group (P = 0.03).  
 Leukocyte counts were significantly lower at after 5 minutes after CPB in the 
PMEA group than the heparin group (P = 0.002) (Table 2).  
  Amounts of D-dimer fibrin, a marker of fibrin degradation, were not 
significantly different between the two groups, whereas amounts of CRP were 
significantly higher in the PMEA group 24hours after the patients was admitted into the 
intensive car unit (ICU) (P = 0.003).  
  Respiratory index were significantly higher just after CPB (P = 0.01) and after 
1 hour after admittance to the ICU in PMEA group (P = 0.01) (Table 3).  
 Hemodynamic data showed that PMEA circuits caused hypotension within 5 
minutes after CPB initiation (SAP, P = 0.01, MAP, P = 0.008, DAP, P = 0.002) (Table 
4). 
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Discussion 
Interaction between blood components and the non-physiological surfaces of CPB 
components (e.g., tubes, oxygenator, reservoir, arterial filter and cannulae) during CPB 
induces several pathophysiologic responses including fibrinolysis, complement 
activation, inflammatory cytokine release, coagulation and bradykinin release, and 
leukocyte, platelet, and endothelial cell activation.12 The consequent whole body 
inflammatory response can ultimately lead to post-perfusion syndrome.13Manufactures 
of CPB equipment have modified ore are currently modifying the surfaces of CPB 
circuits and components. It is well known that coated circuits and components reduce 
CPB-induced inflammation.1 
Unlike traditional non-coated circuits, heparin-coated circuits have the 
potential to improve resource utilization in patients undergoing cardiac surgery.6, 11 
However, new technology and accompanying changes in clinical and surgical practice 
must be validated before implementation to prevent harm to patients.6 Future 
innovations include modification of the polymer resin during manufacture, and coating 
the inner surface of the tubing and oxygenators with additives after they have been 
manufactured.15 
PMEA is a synthetic polymer, that is quickly and easily applied, thus 
eliminating the need for potentially hazardous linkers or organic animal components, 
(e.g., heparin) that may cause, at least to some extent, allergic reactions, 
thrombocytopenia, or bovine spongiform encephalopathy via viral transfer. 12 Previous 
clinical and experimental studies have shown that PMEA surfaces are more compatible 
with platelets, white blood cells, and complement system components and less likely to 
induce process such as coagulation and protein adsorption than uncoated surfaces.5, 12, 17 
As described by Gunaydin et al.20, PMEA coating has a hydrophobic polyethylene 
backbone and a chemically inactive outer surface, and therefore little reactivity with 
blood components. 
Surface structure affects protein adsorption at the molecular level. 21 Both the 
amount and conformation of absorbed proteins play a major role in platelet adhesion. 
Previous studies have shown that coating circuit surfaces with PMEA inhibits protein 
adsorption and the denaturation of adsorbed proteins.8 Significantly less protein is 
adsorbed onto PMEA-coated circuits than uncoated circuits.22  
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  Despite the advantages of PMEA-coated circuits, our results clearly show that 
they cause transient leukopenia during pediatric CPB. Transient leukopenia, mainly 
granulocytopenia and monocytopenia, occurs when circulating cells are trapped within 
the pulmonary vasculature owing to complement activation via a non-traditional 
pathway.23 Exposure of blood to a CPB circuit activates the complement system, mainly 
through this alternative pathway.5,16 CPB circuits do not contain endothelial cells, which 
normally regulate cofactor C3 activity, on their interior wall.5 Therefore when blood 
contacts extracorporeal circuits, it along with kallikrein stimulates the formation of C3a 
and C5a, which have anaphylactic and chemotactic activity.5 Contact of blood with 
negatively charged surfaces cleaves, factor Ⅻ, which is normally present in an inactive 
complex with prekallikrein, factor Ⅺ, and high molecular weight kininogen 
(HMWK).12 The cleavage products (alpha and beta factor Ⅻa) subsequently transduce 
all contact-initiated response. Beta-factor Ⅻa converts inactive prekallikrein into active 
kallikrein, which detaches the vasodilator bradykinin from HMWK.12  
Ikuta et al.21 found that the PMEA-coated circuits better prevented platelet 
activation than heparin-coated and non-coated circuits and perioperatively inhibited the 
activety of inflammatory cytokines to a similar extent as heparin-coated surfaces, but 
were slightly inferior in reducing complement activation. Complement activation leads 
to neutrophil activation,13, 22 which explains why our results show significantly lower  
leukocyte counts for PMEA-coated circuits than heparin-coated circuits at the beginning 
of CPB. From this, it can be inferred that PMEA-coated circuits activates complement 
via the alternative pathway and entraps leukocytes within the pulmonary vasculature. 
Accordingly, the transient leucopenia caused by PMEA-coated circuits reduces 
perfusion pressure during pediatric CPB and may leads lower hemodynamic data during 
surgery.  
Our results also clearly show that PMEA-coated circuits have a higher RI than 
heparin-coated circuits just after CPB and 1 hour after transfer of the patient to the ICU. 
They were also associated with significantly higher CRP levels 24 hours after transfer to 
the ICU. Hazama et al.22 showed that neutrophil elastase levels were significantly lower 
for heparin-coated circuits than PMEA-coated circuits immediately and 4 hours after 
CPB. Transient leukopenia may account for post-CPB increases in the RI and CRP 
levels in patients receving PMEA-coated circuits. Increasing in the after CPB predict 
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development of SIRS as a result of post-perfusion syndrome.24, 25 However, the 
differences of between Heparin and PMEA groups; amount of red blood cells transfused 
during surgery may influence the RI, CRP level and hemodynamic change during 
surgery.26, 27  
 CPB circuit coating may system be of greater importance in pediatric patients than 
adult patients owing to the relatively large interface between the artificial surface 
interface and the blood.16 Pediatric patients are at particular risk for post-operative 
coagulation because of increased hemodilution in pediatric CPB, and a higher ratio of 
the internal surface area of the circuit to blood volume in children than adults. 
Additional patient-related factors include chronic cyanosis and polycythemia, which are 
more common in patients with congenital heart disease. 15−17 On the basis of the results 
of our study, we recommend the use of heparin-coated circuits than PMEA-coated 
circuits for pediatric CPB.  
  The major limitation of the present study was small sample size. In summary, 
our findings show that PMEA-coated circuits unlike heparine-coated circuits, cause 
transient leukopenia during pediatric CPB. They also tended to cause systemic 
inflammatory respiratory syndrome after CPB. Therefore, we concluded that heparin-
coated circuits are better than PMEA-coated circuits in pediatric CPB.  
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Figure Legend 
 
Table 1: Patient Demographic and Clinical Variables 
PMEA: poly-2-mthoxyehyl acrylate, CPB: cardiopulmonary bypass, MUF: modified ultrafiltration 
Data are reported as median and range. 
†P<0.05, heparin versus PMEA 
 
Table 2: Perioperative Clinical Variables 
Data are reported as median and range. Power analysis was higher than 0.6 for all data. 
†P<0.05, heparin versus PMEA 
*P<0.05, after induction of anesthesia versus 5 min after CPB 
PMEA: poly-2-mthoxyehyl acrylate, CPB: cardiopulmonary bypass, ICU: intensive care unit, CRP: C-reactive 
protein 
 
Table 3: Changes in the Respiratory Index 
Data are reported as median and range. Power analysis was higher than 0.6 for all data. 
†P<0.05, heparine versus PMEA 
PMEA: poly-2-mthoxyehyl acrylate, CPB: cardiopulmonary bypass, ICU: intensive care unit  
 
Table 4: Hemodynamic change during CPB  
Data are reported as median and range. Power analysis were higher than 0.6 for all data. 
†P<0.05, heparine versus PMEA 
PMEA: poly-2-mthoxyehyl acrylate, CPB: cardiopulmonary bypass, ICU: intensive care unit  
 
